Abstract:The cascade of amyloid formation relates to multiple complex events at the molecular level. Previous research has established amyloid plaque deposition as the leading cause of Alzheimer's disease (AD) pathogenesis, detected mainly in aged population. The primary components of the plaques are two alloforms of amyloid-beta (Aβ), Aβ1-42 and Aβ1-40 peptides. Recent studies have provided considerable evidence contrary to the previous claim indicating that amyloid-beta oligomers (AβOs) as the main culprit responsible for AD-associated neurotoxicity and pathogenesis. In this review, we have discussed the primary features of AβOs, such as assembly formation, the kinetics of oligomer formation, interactions with various membranes/membrane receptors, the origin of toxicity, and oligomer-specific detection methods. Recently, the discovery of rationally designed antibodies has opened a gateway for using synthesized peptides as a grafting component in the complementarity determining region (CDR) of antibodies. Thus, the Aβ sequence motif or the complementary peptide sequence in the opposite strand of the β-sheet (extracted from the Protein Data Bank: PDB) helps design oligomer-specific inhibitors. The microscopic event responsible for oligomer formation can be targeted, and thus prevention of the overall macroscopic behaviour of the aggregation or the associated toxicity can be achieved. We have carefully reviewed the oligomer formation kinetics and associated parameters. Besides, we have depicted a thorough understanding of how the synthesized peptide inhibitors can impede the early aggregates (oligomers), mature fibrils, monomers, or a mixture of the species. The oligomer-specific inhibitors (peptides or peptide fragments) lack in-depth chemical kinetics and optimization control-based screening. In the present review, we have proposed a hypothesis for effectively screening oligomer-specific inhibitors using the chemical kinetics (determining the kinetic parameters) and optimization control strategy (cost-dependent analysis). Further, it may be possible to implement the structure-kinetic-activity-relationship (SKAR) strategy instead of structure-activity-relationship (SAR) to improve the inhibitor's activity. The controlled optimization of the kinetic parameters and dose usage will be beneficial for narrowing the search window for the inhibitors.

Polyoxometalates As Inhibitors of the Aggregation of Amyloid Β Peptides Associated with Alzheimer’s Disease

Targeting protein aggregation: the promising application of polyoxometalates in neurodegenerative diseases

Enantioselective Modulation of Amyloid Burden and Memory Deficits by Chiral Polyoxometalates for Alzheimer's Disease Treatment

Organoplatinum‐Substituted Polyoxometalate Inhibits Β‐amyloid Aggregation for Alzheimer's Therapy

Metal-Organic Frameworks Harness Cu Chelating and Photooxidation Against Amyloid β Aggregation in Vivo

Modulating Conformation of Aβ-Peptide: an Effective Way to Prevent Protein-Misfolding Disease

Aβ42-binding peptoids as amyloid aggregation inhibitors and detection ligands.

Recent Developments in the Chemical Biology of Amyloid-Β Oligomer Targeting

Copolymer Polydopamine Nanoparticles as Multifunctional Nanoinhibitors for Modulating β-Amyloid Aggregation

Polyallylamine Binds to Aβ Amyloid and Inhibits Antibody Recognition

Molecular Integrative Analysis of the Inhibitory Effects of Dipeptides on Amyloid β Peptide 1–42 Polymerization

Understanding the Molecular Mechanisms of Polyphenol Inhibition of Amyloid β Aggregation

Molecular Integrative Study on Inhibitory Effects of Pentapeptides on Polymerization and Cell Toxicity of Amyloid-β Peptide (1–42)

Promising application of polyoxometalates in the treatment of cancer, infectious diseases and Alzheimer's disease

Polyoxometalate-Decorated Gold Nanoparticles Inhibit β-Amyloid Aggregation and Cross the Blood-Brain Barrier in a µphysiological Model

Aβ-oligomers: A potential therapeutic target for Alzheimer's disease

Anti-Aβ42 Aggregative Polyketides from the Antarctic Psychrophilic Fungus Pseudogymnoascus sp. OUCMDZ-3578

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer's Disease, Parkinson's Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis.

Porous organic cage as an inhibitor of Aβ42 peptide: a simulation study

Nanomaterials for Modulating the Aggregation of -Amyloid Peptides

Amyloid Oligomers: A Joint Experimental/Computational Perspective on Alzheimer’s Disease, Parkinson’s Disease, Type II Diabetes, and Amyotrophic Lateral Sclerosis